Deep mutational scanning of proteins in mammalian cells
S Maes, N Deploey, F Peelman, S Eyckerman - Cell Reports Methods, 2023 - cell.com
Protein mutagenesis is essential for unveiling the molecular mechanisms underlying protein
function in health, disease, and evolution. In the past decade, deep mutational scanning …
function in health, disease, and evolution. In the past decade, deep mutational scanning …
Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants
L Mao, Y Wang, L An, B Zeng, Y Wang, D Frishman… - Biology, 2023 - mdpi.com
Simple Summary Hearing loss is the most common sensory impairment in humans. Globally,
GJB2 is the most common responsible gene, with missense variants being the most frequent …
GJB2 is the most common responsible gene, with missense variants being the most frequent …
Saturation profiling of drug-resistant genetic variants using prime editing
Methods to characterize the functional effects of genetic variants of uncertain significance
(VUSs) have been limited by incomplete coverage of the mutational space. In clinical …
(VUSs) have been limited by incomplete coverage of the mutational space. In clinical …
Preclinical Anticipation of On-and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
PJ Dziubańska-Kusibab, E Nevedomskaya… - International Journal of …, 2024 - mdpi.com
The advent of targeted therapies has led to tremendous improvements in treatment options
and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by …
and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by …
[HTML][HTML] The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review
A Belloni, A Pugnaloni, MR Rippo, S Di Valerio… - Critical Reviews in …, 2024 - Elsevier
Abstract Non-Small Cell Lung Cancer (NSCLC) represents∼ 85% of all lung cancers and∼
15–20% of them are characterized by mutations affecting the Epidermal Growth Factor …
15–20% of them are characterized by mutations affecting the Epidermal Growth Factor …
Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation
Y Wang, Q Liu, C Chu, L Li, Z Wang, Q Liu, G Wu… - Toxicology and Applied …, 2023 - Elsevier
Lung cancer, the leading cause of cancer-related mortality, is the most commonly diagnosed
cancer. Tyrosine kinase inhibitors (TKIs) are considered a drug-targeted therapy for non …
cancer. Tyrosine kinase inhibitors (TKIs) are considered a drug-targeted therapy for non …
A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells
L Li, C Liu, R Wang, X Yang, X Wei, C Chu, G Zhang… - Scientific Reports, 2024 - nature.com
Mutations in the epidermal growth factor receptor (EGFR) gene are common driver
oncogenes in non-small cell lung cancer (NSCLC). Studies have shown that afatinib is …
oncogenes in non-small cell lung cancer (NSCLC). Studies have shown that afatinib is …
Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing
Variants of uncertain significance (VUS) hamper the clinical application of genetic
information. For example, in treating lung cancer with tyrosine kinase inhibitors (TKIs), many …
information. For example, in treating lung cancer with tyrosine kinase inhibitors (TKIs), many …
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
Z Wang, L Li, C Chu, X Wei, Q Liu… - International …, 2023 - spandidos-publications.com
Bladder cancer is one of the most common urological malignancies worldwide. The
molecular mechanism underlying its development is complex, but its carcinogenesis has …
molecular mechanism underlying its development is complex, but its carcinogenesis has …
Validation and benchmarking of targeted panel sequencing for cancer genomic profiling
D Wang, S Wang, Y Zhang, X Cheng… - American Journal of …, 2023 - academic.oup.com
Objectives To validate a large next-generation sequencing (NGS) panel for comprehensive
genomic profiling and improve patient access to more effective precision oncology treatment …
genomic profiling and improve patient access to more effective precision oncology treatment …